The Perception of Neighbour in CMLL Publicistics

This article deals with the content of neighbour on the basis of the forms of the noun ‘neighbour’ (Lith. kaimynas). Efforts are made to strike a balance between the structural and the cognitive approach to its meaning. The sample base for the study consists of 700 published sentences sourced in the Corpus of the Modern Lithuanian Language (CMLL) compiled by the Centre for Computational Linguistics at the Vytautas Magnus University in Kaunas.The study has revealed a neighbour to be someone who experiences a certain mental state, someone who, in his or her (un)favourable response to the environment, affects another person in a relatively close space. Emotionally charged, this effect shows a neighbour who is a nice or a bad person to live next-doors with. The (dis)harmony of attitudes, values, and actions grounded on an (un)favourable mind-set defines a dynamic coexistenceof neighbours, or a failure to coexist.When it comes to the perception of neighbour that shifts in time, what matters is the shared space of the neighbours that has its relative boundaries and is measured as a distance – the closeness resulting in the distinction between a close > distant neighbour; yet even more important is the camaraderie – the proximity of attitudes, values, and the actions that they define – something that the dictionary definitions of the word neighbour tend to omit – and the related gradational differences between a homey > strange neighbour. When it comes to building and maintaining proximity, it is the neighbour’s temper, polite and supportive interaction, and behaviour that favours another person, such as sharing things with them and all kinds of assistance, especially in need, that matters. As the mind-sets, values, and behaviours assimilate, the neighbours become one – they become homey to each other. And the axis of oneness grounded on favour in neighbourhood is God.

Predictive value of post-implantation frontal QRS-T angle in patients receiving cardiac resynchronization therapy

Funding Acknowledgements Type of funding sources: None. Objective Favourable response criteria for cardiac resynchronization therapy (CRT) implantation are still under debate. We investigated the relationship between frontal QRS-Tangle and improvement of functional New York Heart Association (NYHA) class and thus favourable response to CRT. Method Eighty-one patients were included in the study who CRT implanted. ECG and echocardiography were obtained 1 week before and after six month-1 years the CRT procedure. Patients were classified as "NYHA improvement" and "NYHA non-improvement" according to their NYHA class. The frontal QRS-T angle was calculated the absolute value of the difference between the QRS and T wave axes [Frontal QRS-Tangle=(QRS axis-T axis)] Results The mean age of patients was 64.5 ± 9.1 years. There was no difference between two groups in terms of demographic features. The post-implantation LVEF was higher in patients NYHA improvement group (p < 0.001). Post–implantation QRS duration (p = 0.008), cQT interval (p = 0.012), frontal QRS-T angle (p = 0.003) values were very shorter in NYHA improvement group (Table 1). In multivariate regression analysis showed the frontal QRS-T angle and age independent risk factors for improvement of NYHA class (p < 0.05). The receiver operating characteristics curve analysis (ROC) were showed the optimal cut-off value of predicting NYHA improvement for frontal QRS-Tangle was < 135 (AUC:0.69, 95%CI 0.575-0.814, p = 0.004). Conclusion: We found that after CRT implantation, functional NYHA class improvement was associated the shortened of QRS, cQT interval, increased LVEF and narrowed of the frontal QRS-Tangle (<135 ms) was in both ischemic and non-ischemic patients Table 1 variables NYHA improvement group(43) NYHA non-improvement group (n = 34) p value age (years) 61.1 ± 9.9 66.5 ± 8.9 0.017 Post-implantation EF (%) 39 (30-50) 30 (20-37) <0.001 Pre-CRT Frontal QRS-T angle (º) 153.0 ± 57.8 155.7 ± 56.7 0.840 Post-CRT Frontal QRS-T angle (º) 118.4 ± 69.7 168.1 ± 67.8 0.003 Table 1

A CASE OF A CHRONIC LYMPHOPROLIFERATIVE DISORDER PRESENTING AS AUTOIMMUNE HEMOLYTIC ANEMIA

Lymphoproliferative disorders encompass a group of diseases with a highly variable clinical course. This is a case report of a patient who presented with haemolytic anemia initially and was subsequently diagnosed as a chronic lymphoproliferative disorder. He was treated with Rituximab to which he showed a favourable response.

Resolution of bilateral foveal cysts in dome-shaped macula after treatment with topical dorzolamide

Dome-shaped macula (DSM) is characterised by a convex anterior bulging of the macular area. It can further get complicated by accumulation of subretinal fluid (SRF). Foveal cysts that are bilateral, in a setting of DSM, are an entity not yet reported. Management options for DSM with SRF showed variable success. Topical carbonic anhydrase inhibitors (CAIs) have been successful in treating certain macular pathologies. The authors report a rare case of bilateral intraretinal foveal cyst in a myopic child with DSM with favourable response to topical dorzolamide. Topical CAIs may be considered a safe and effective option in such cases.

Could T-wave and T peak-end interval be a new prognostic marker for patients receiving after cardiac resynchronization therapy?

Background:In this study, we investigated predictors of favourable responses to CRT using electrocardiography parameters in heart failure patients. Methods : Seventy-two patients with heart failure, sinus rhythm, left bundle branch block and receiving CRT were included in the study. Patients were classified as “responders” with an improvement in ejection fraction of 10% and “non-responders” as any patient not meeting this definition. Electrocardiograms were evaluated before and after 6 months CRT implantation. Results: There was no difference between responder and non-responder groups in terms of age, co-morbidities, medications, pre-implantation ECG parameters (p>0.05). A number of women CRT-responders higher than non-responder (25.4 % vs 6 %, p=0.026), and NYHA Class III patients dominantly in CRT-responder groups (36.9 % vs 29.2 %, p=0.014, respectively).Post–implantation QRS duration (143.3± 18.6 vs 160.1 ± 29.2 ms), cQT interval (474.8 ± 43.4 vs 502.7 ± 49.6 ms), T-wave (165.6 ± 25.7 vs 192.1 ± 25.0 ms) and T peak-end (82.9 ± 13.2 vs 98.1 ± 13.3 ms) values were very shorter in CRT responders group (p<0.05). In univariate regression analyses showed shortening of QRS, QT interval, T-wave, Tpeak-end interval associated with favourable response to CRT (p<0.05). The receiver operating characteristics curve analyses were showed the optimal cut-off T-wave <182 ms, with 76 % sensitivity, 75 % specificity, and Tpeak-end interval < 92 ms with 80 % sensitivity, for the favourable response CRT (p<0.05). Conclusion: QRS duration and QT interval narrowing are known to be associated with favourable outcomes, although the T-wave duration and T peak-to-end interval may also be considered in heart failure patients to predict a favourable CRT response.

P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).

TPS425 Background: Bleomycin, etoposide, cisplatin (BEP) given 3-weekly x 4 remains standard 1st line chemotherapy for metastatic GCTs. Acceleration of standard regimen with shorter cycle lengths has improved cure rates in other cancers. This is the first international randomised clinical trial for intermediate and poor-risk metastatic extracranial GCTs involving both adult and paediatric age group males and females. We aim to determine if accelerated BEP is superior to standard BEP. Methods: DESIGN: Open label, randomised, stratified multicentre, 2 stage, phase 3 trial. Primary endpoint for stage I (n = 150) is the achievement of a favourable response, and for entire trial (n = 500) is progression free survival (PFS). SAMPLE SIZE: 150 and 500 patients gives > 80% power to detect a 20% improvement in the favourable response rate and 7% absolute improvement in 2yr PFS, respectively. POPULATION: Males and females aged 11-45 years with intermediate or poor-risk metastatic GCTs of the testis, ovary, retroperitoneum or mediastinum for 1st line chemotherapy. TREATMENT: Randomisation 1:1 to 4 cycles of “standard BEP” or “accelerated BEP”: cisplatin 20mg/m2 IV D1-5; etoposide 100mg/m2 IV D1-5; bleomycin 30000 IU IV weekly; and pegylated G-CSF SC D6 or filgrastim daily; given every 3 weeks or every 2 weeks respectively. Accelerated BEP arm receives 4 additional weekly doses of bleomycin. ASSESSMENTS: Response assessments at 30 day safety assessment, and 6 months from randomisation or after all post-chemotherapy intervention is completed. Regular follow-up up to 5 years, then annually. Archival tumour tissue and baseline blood collected for translational substudies. STATUS: 25 sites open in ANZ, 13 sites open in UK (led by Cambridge Clinical Trials Unit), 67 sites open in the USA (led by Children’s Oncology Group). As of September 2019, 98 patients have been recruited triggering the first formal interim analysis. Clinical trial information: NCT02582697.